Preexposure Prophylaxis in HIV Serodiscordant Couples

Partners PrEP Trial
Oral HIV PrEP for Heterosexual Couples in Kenya and Uganda

Partners PrEP: Study Design

**Background**: Randomized, placebo-controlled trial that examined efficacy and safety of tenofovir DF and tenofovir DF-emtricitabine as HIV PrEP in heterosexual HIV-1 serodiscordant couples from Kenya and Uganda

**Inclusion Criteria** (4,758 enrolled)
- 18 years of age or older
- HIV-1-serodiscordant couples
- HIV-seropositive partner: not receiving ART and did not meet Kenyan or Ugandan guidelines for initiation of ART
- HIV-seronegative partners: normal renal function; not infected with HBV; not breastfeeding

**Treatment Arms**
- Placebo: 1 pill daily
- Tenofovir DF: 1 pill daily
- Tenofovir DF-emtricitabine: 1 pill daily

4,758 Heterosexual, HIV-1-Serodiscordant Couples

n = 1808

Placebo
(n = 1,584)

Tenofovir DF
(n = 1,584)

Tenofovir DF-Emtricitabine
(n = 1,579)

n = 2950

HIV Status

11 total couples found to be ineligible and not included in the intention-to-treat analysis.


Number of HIV-1 Infections

Study stopped July 2011 by DSMB because of PrEP efficacy

Oral HIV PrEP for Heterosexual Couples in Kenya and Uganda

Partners PrEP: Results

Risk Reduction Compared with Placebo

Study stopped July 2011 by DSMB because of PrEP efficacy


HIV Risk Reduction Based on Gender of Seronegative Partner

Risk Reduction Compared with Placebo (%)

<table>
<thead>
<tr>
<th>Seronegative Partner</th>
<th>All</th>
<th>Women</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenofovir DF</td>
<td>67</td>
<td>71</td>
<td>63</td>
</tr>
<tr>
<td>Tenofovir DF-Emtricitabine</td>
<td>75</td>
<td>66</td>
<td>84</td>
</tr>
</tbody>
</table>

Study stopped July 2011 by DSMB because of PrEP efficacy

Conclusions: “Oral tenofovir DF and tenofovir DF- emtricitabine both protect against HIV-1 infection in heterosexual men and women.”
Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.